These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32715722)

  • 1. A Clinical Review of Biosimilars Approved in Oncology.
    Ngo D; Chen J
    Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
    Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
    Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis.
    Luo X; Du X; Li Z; Liu J; Lv X; Li H; Guo Q; Wang C; Xue X; Le K; Jiang X; Huang L; Yang Y
    JAMA Netw Open; 2023 Oct; 6(10):e2337348. PubMed ID: 37824143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
    Giuliani J; Bonetti A
    Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies.
    Safdar A; Butt MH; Ahmad A; Zaman M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1195-1204. PubMed ID: 34096401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The development of biosimilars in oncology].
    Jiang SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A descriptive analysis of real-world oncology biosimilar use in Japan.
    Roth JA; Rahshenas M; Nowacki G; Masurkar N; Shelbaya A; Tajima K; Dorman S; Ono C
    Future Oncol; 2024; 20(25):1837-1850. PubMed ID: 38864611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinician's guide to biosimilars in oncology.
    Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
    Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars in oncology: Effects on economy and therapeutic innovations.
    Hübel K; Kron F; Lux MP
    Eur J Cancer; 2020 Nov; 139():10-19. PubMed ID: 32950935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
    Waterhouse DM; Ward P; Drosick DR; Burdette C; Davies D; Mendenhall MA
    JCO Oncol Pract; 2023 Nov; 19(11):1053-1057. PubMed ID: 37738533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
    Hara F; Tajima K; Tanabe K
    Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review.
    Coory M; Thornton K
    Breast Cancer Res Treat; 2019 Jul; 176(1):17-25. PubMed ID: 30980209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.